We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Reporting of MABp1 for the Treatment of Psoriasis

Bobbak Mansouri, MD1; Alan Menter, MD1
[+] Author Affiliations
1Division of Dermatology, Baylor University Medical Center, Dallas, Texas
JAMA Dermatol. 2015;151(10):1143-1144. doi:10.1001/jamadermatol.2015.1684.
Text Size: A A A
Published online


To the Editor We were interested to read the report by Coleman et al1 in which they administered a novel interleukin (IL)-1α inhibitor, MABp1, to 8 patients with plaque psoriasis over 8 weeks in an open-label study. The issue of plaque psoriasis treatment is important because IL-1 inhibitors have shown some promise in treating generalized pustular psoriasis, an uncommon variant of psoriasis, which appears to be IL-1 mediated.2,3 Since all 5 biological therapies approved for use in moderate to severe plaque psoriasis—adalimumab, etanercept, infliximab, secukinumab, and ustekinumab—have better PASI 75 response rates (Psoriasis Area and Severity Index of ≥75) than the 13% improvement seen in the report on MABp1, it would seem that the statement that “the clinical responses…are encouraging”1(p556) should be tempered. By comparison, the PASI 75 response rates for adalimumab, etanercept, infliximab, ustekinumab, and secukinumab are 71% (16 weeks), 49% (12 weeks), 80% (10 weeks), 66% to 67% (12 weeks), and 77% to 82% (12 weeks), respectively.4,5


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





October 1, 2015
Kyle M. Coleman, MD; Johann E. Gudjonsson, MD, PhD; Michael Stecher, MD
1Westlake Dermatology and Cosmetic Surgery, Austin, Texas
2Department of Dermatology, University of Michigan, Ann Arbor, Michigan
3XBiotech USA Inc, Austin, Texas
JAMA Dermatol. 2015;151(10):1144. doi:10.1001/jamadermatol.2015.1683.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...